This study was designed to determine if ET-1 levels are higher in AD patients compared to controls; if so, then this would be the basis for determining if this vasoconstrictor would play a role in AD development as well as help to explain the racial disparity seen in African Americans with AD compared to non-Hispanic White patients with AD. The gene discussed is EDN1; the disease is Alzheimer disease.